Literature DB >> 16462489

Increased expression of 5-lipoxygenase in high-grade astrocytomas.

Narendra Nathoo1, Richard A Prayson, Judy Bondar, Linda Vargo, Susana Arrigain, Edward J Mascha, John H Suh, Gene H Barnett, Mladen Golubic.   

Abstract

OBJECTIVE: 5-Lipoxygenase (5-LO) oxidizes arachidonic acid into proinflammatory eicosanoids that may promote tumorigenesis. In this study, we investigated whether 5-LO is expressed in human astrocytomas and what effect its expression may have on patient outcome.
METHODS: Increased 5-LO messenger ribonucleic acid and protein expression was detected by the polymerase chain reaction and antibody-based approaches, respectively, in surgical astrocytoma specimens and established glioblastoma multiforme cell lines compared with primary cell culture from the human white matter.
RESULTS: Immunohistochemical analysis revealed predominantly nuclear 5-LO staining in 44 of 49 glioblastoma multiforme samples (90%), 8 of 10 (80%) anaplastic astrocytomas samples, and 3 of 13 (23%) low-grade astrocytoma samples analyzed. Double-staining experiments with anti-CD-68 (macrophage/microglial marker) and anti-5-LO antibodies suggest that both CD-68-positive and CD-68-negative tumor cells express 5-LO protein. Staining of 5-LO was significantly more frequent in high-grade than in low-grade tumors (P = 0.001). Patients whose tumors expressed 5-LO were significantly older, had lower preoperative Karnofsky performance scores and shorter survival than patients whose tumors did not express 5-LO. After adjusting for pathological diagnosis and age, respectively, neither Karnofsky performance score nor survival were significantly associated with 5-LO staining.
CONCLUSION: These data indicate that 5-LO is overexpressed in high-grade astrocytomas and supports the idea that eicosanoids may play a role in tumorigenesis of these brain tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16462489     DOI: 10.1227/01.NEU.0000195096.43258.94

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  10 in total

1.  Association between 5-lipoxygenase expression, and malignant behaviors and poor prognosis in esophageal squamous cell carcinoma.

Authors:  Chun-Ying Bai; Jun-Yi Zhang; Tie-Wei Shi; Yu-Qin Bai; Bing-Li Wu; Ze-Peng Du; Zhi-Yong Wu; Xiu-E Xu; Shao-Hong Wang; Jian-Yi Wu; Rui-Yun Te; Jing-Yi Zhang; Li-Yan Xu; En-Min Li
Journal:  Oncol Lett       Date:  2018-04-18       Impact factor: 2.967

2.  An inhibitor of arachidonate 5-lipoxygenase, Nordy, induces differentiation and inhibits self-renewal of glioma stem-like cells.

Authors:  Bin Wang; Shi-cang Yu; Jian-yong Jiang; Gavin Wallace Porter; Lin-tao Zhao; Zhe Wang; Hong Tan; You-hong Cui; Cheng Qian; Yi-fang Ping; Xiu-wu Bian
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

3.  Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection.

Authors:  Rosalina Wisastra; Petra A M Kok; Nikolaos Eleftheriadis; Matthew P Baumgartner; Carlos J Camacho; Hidde J Haisma; Frank J Dekker
Journal:  Bioorg Med Chem       Date:  2013-10-23       Impact factor: 3.641

4.  Co-expression of COX-2 and 5-LO in primary glioblastoma is associated with poor prognosis.

Authors:  Xingfu Wang; Yupeng Chen; Sheng Zhang; Lifeng Zhang; Xueyong Liu; Li Zhang; Xiaoling Li; Dayang Chen
Journal:  J Neurooncol       Date:  2015-09-03       Impact factor: 4.130

5.  Expression of VAV1 in the tumour microenvironment of glioblastoma multiforme.

Authors:  Juan Luis Garcia; Jose Couceiro; Juan Antonio Gomez-Moreta; J M Gonzalez Valero; Angel Santos Briz; Vincent Sauzeau; Eva Lumbreras; Manuel Delgado; Cristina Robledo; Monica Lara Almunia; Xose R Bustelo; Jesus M Hernandez
Journal:  J Neurooncol       Date:  2012-08-04       Impact factor: 4.130

6.  The 1,4 benzoquinone-featured 5-lipoxygenase inhibitor RF-Id induces apoptotic death through downregulation of IAPs in human glioblastoma cells.

Authors:  S Zappavigna; M Scuotto; A M Cossu; D Ingrosso; M De Rosa; C Schiraldi; R Filosa; M Caraglia
Journal:  J Exp Clin Cancer Res       Date:  2016-10-22

7.  Substituted Caffeic and Ferulic Acid Phenethyl Esters: Synthesis, Leukotrienes Biosynthesis Inhibition, and Cytotoxic Activity.

Authors:  Pier Morin; Patrick-Denis St-Coeur; Jérémie A Doiron; Marc Cormier; Julie J Poitras; Marc E Surette; Mohamed Touaibia
Journal:  Molecules       Date:  2017-07-06       Impact factor: 4.411

Review 8.  A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.

Authors:  Richard E Kast; John A Boockvar; Ansgar Brüning; Francesco Cappello; Wen-Wei Chang; Boris Cvek; Q Ping Dou; Alfonso Duenas-Gonzalez; Thomas Efferth; Daniele Focosi; Seyed H Ghaffari; Georg Karpel-Massler; Kirsi Ketola; Alireza Khoshnevisan; Daniel Keizman; Nicolas Magné; Christine Marosi; Kerrie McDonald; Miguel Muñoz; Ameya Paranjpe; Mohammad H Pourgholami; Iacopo Sardi; Avishay Sella; Kalkunte S Srivenugopal; Marco Tuccori; Weiguang Wang; Christian R Wirtz; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2013-04

9.  CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.

Authors:  Richard E Kast; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2014-09-30

10.  Kukoamine A inhibits human glioblastoma cell growth and migration through apoptosis induction and epithelial-mesenchymal transition attenuation.

Authors:  Qiaoping Wang; Haiyan Li; Zhen Sun; Lihua Dong; Ling Gao; Chunlan Liu; Xiujie Wang
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.